Found 2,528 articles
All that is lacking from the likely drama surrounding patent battles over CRISPR technology in the U.S. Court of Appeals today is Michael Buffer’s cry of “Let’s get ready to rumble.”
Global Genome Editing Market - Industry Analysis and Forecast| Technavio
Technavio’s latest market research report on the global genome editing market provides an analysis of the most important trends expected to impact the market outlook from 2018-2022.
Mammoth Biosciences, based in San Francisco, has officially launched to develop CRISPR technology for clinical diagnostics.
Vertex Reports First-Quarter 2018 Financial Results
Vertex Pharmaceuticals Incorporated reported consolidated financial results for the first quarter ended March 31, 2018.
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation
CAR-T Trailblazer Carl June Who Collaborated on Novartis’ Kymriah Makes Time's 100 Influential List
4/23/2018A pioneer in CAR-T therapies has been named one of Time Magazine’s 100 most influential people in the world for 2018.
Bluebird bio announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia (TDT).
The plan is to treat patients with beta thalassemia, a blood disorder that decreases the production of hemoglobin, the iron-containing protein in red blood cells that carries oxygen.
Synthego Appoints CRISPR Pioneer Dr. Jennifer Doudna to Advisory Board to Accelerate Company's Genome Engineering Mission
Doudna to advise Synthego as the company develops technology and services to further the adoption of CRISPR, bringing access, precision and automation to genome engineering
Kaleido Biosciences Announces Appointments to Leadership Team
Stephen Sofen, Ph.D. to head technical operations and Susan Stewart, J.D. to lead regulatory affairs and quality
CureVac Receives U.S. Patent Covering Entire Process for Pharmaceutical Manufacturing of RNA
CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance to CureVac on GMP-conforming pharmaceutical manufacturing methods for producing RNA
IDEAYA Biosciences Raises $94 Million Crossover Series B Financing
Proceeds to advance multiple synthetic lethality and immuno-oncology therapies into the clinic
Concert Pharmaceuticals Reports Year Ended 2017 Financial Results
CTP-543 on track to report topline Phase 2a results in Alopecia Areata by year-end.
Magenta Therapeutics Presents Clinical and Preclinical Data at ASBMT Conference, Including New Preclinical Results on Microglial Engraftment with MGTA-456 Expanded Cord Blood Stem Cell Product
Five presentations of clinical and preclinical data from Magenta programs –Two presentations named among best in conference.
Gilead’s Kite Teams Up with Sangamo Therapeutics for Cancer Therapeutics in a $3.1 Billion+ Deal
2/22/2018Kite, a Gilead Company, has inked a worldwide collaboration deal with Sangamo Therapeutics to develop oncology therapeutics.
MilliporeSigma Receives Two More Patents for CRISPR Technology
MilliporeSigma announced that the Korean Intellectual Property Office and the Israel Patent Office have each granted patent applications for the company's CRISPR technology used in a genomic-integration method for eukaryotic cells.
4 Small Biotech M&A Targets for Gilead
2/15/2018Investors and analysts had been encouraging Gilead to acquire something for a long time, so they were mostly happy when it bought Kite Pharma in September.
Two Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells
Cellectis announced today the issuance of two U.S. patents - US 9,855,297 and US 9,890,393 - for the invention of certain uses of RNA-guided endonucleases, such as Cas9 or Cpf1, for the genetic engineering of T-cells.
CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria
CureVac today announced the awarding of two new grants from the Bill & Melinda Gates Foundation.
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease
Infantile Batten disease is an inherited fatal genetic disease that primarily affects the nervous system in newborns and progresses rapidly.